Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in …
1. 系统已在2026-08-30 22:40:42对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
J Soung, Y Cui, R Bissonnette, MG Lebwohl…
Journal of the American …, 2026
Elsevier
Continuous icotrokinra demonstrated superior maintenance of skin responses versus placebo through week 52 in adults with moderate-to-severe plaque psoriasis, indicating that once-daily icotrokinra can achieve and maintain skin clearance with a favorable safety profile.Data sharing statement The data sharing policy of Johnson

